Cargando…
Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis
OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN pu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619916/ https://www.ncbi.nlm.nih.gov/pubmed/37920836 http://dx.doi.org/10.3389/fneur.2023.1186420 |
_version_ | 1785130095406481408 |
---|---|
author | Zhang, Fei Yu, Yunfeng Yin, Shuang Hu, Gang Yang, Xinyu Tong, Keke Yu, Rong |
author_facet | Zhang, Fei Yu, Yunfeng Yin, Shuang Hu, Gang Yang, Xinyu Tong, Keke Yu, Rong |
author_sort | Zhang, Fei |
collection | PubMed |
description | OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN published before 31 January 2023 were searched in eight commonly used databases. After screening and confirming the included studies, meta-analysis and trial sequential analysis were performed. RESULTS: A total of 10 relevant studies were confirmed, and the total sample size was 927 cases. On the efficacy endpoints, meta-analysis showed that compared with other administration methods, acupoint injection of mecobalamin significantly increased the clinical effective rate by 27% [RR = 1.27, 95% CI = (1.19, 1.36), P < 0.00001], motor nerve conduction velocity (median nerve) by 5.93 m/s [MD = 5.93, 95% CI = (4.79, 7.07), P < 0.00001], motor nerve conduction velocity (common peroneal nerve) by 5.66 m/s [MD = 5.66, 95% CI = (2.89, 8.43), P < 0.0001], sensory nerve conduction velocity (median nerve) by 4.83 m/s [MD = 4.83, 95% CI = (3.75, 5.90), P < 0.00001], and sensory nerve conduction velocity (common peroneal nerve) by 3.60 m/s [MD = 3.60, 95% CI = (2.49, 4.71), P < 0.00001], and trial sequential analysis showed these benefits were conclusive. In terms of safety endpoints, meta-analysis indicated that the total adverse events for acupoint injection were comparable to other methods of administration, and trial sequential analysis suggested that the results needed to be validated by more studies. Subgroup analysis demonstrated that the benefits of acupoint injections of mecobalamin were not limited by the dose, duration of treatment, or number of acupoints reported in the included studies. Harbord's test showed no significant publication bias (P = 0.106). CONCLUSION: The efficacy of acupoint injection of mecobalamin for DPN was significantly better than other administrations, and its safety was comparable to other administrations. Therefore, acupoint injection may be the optimal method of mecobalamin for DPN. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=454120, identifier: CRD42023454120. |
format | Online Article Text |
id | pubmed-10619916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106199162023-11-02 Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis Zhang, Fei Yu, Yunfeng Yin, Shuang Hu, Gang Yang, Xinyu Tong, Keke Yu, Rong Front Neurol Neurology OBJECTIVE: Mecobalamin is a commonly used drug in the treatment of diabetic peripheral neuropathy (DPN). This study aimed to systematically evaluate the efficacy and safety of acupoint injection of mecobalamin for DPN. METHODS: Relevant clinical trials on acupoint injection of mecobalamin for DPN published before 31 January 2023 were searched in eight commonly used databases. After screening and confirming the included studies, meta-analysis and trial sequential analysis were performed. RESULTS: A total of 10 relevant studies were confirmed, and the total sample size was 927 cases. On the efficacy endpoints, meta-analysis showed that compared with other administration methods, acupoint injection of mecobalamin significantly increased the clinical effective rate by 27% [RR = 1.27, 95% CI = (1.19, 1.36), P < 0.00001], motor nerve conduction velocity (median nerve) by 5.93 m/s [MD = 5.93, 95% CI = (4.79, 7.07), P < 0.00001], motor nerve conduction velocity (common peroneal nerve) by 5.66 m/s [MD = 5.66, 95% CI = (2.89, 8.43), P < 0.0001], sensory nerve conduction velocity (median nerve) by 4.83 m/s [MD = 4.83, 95% CI = (3.75, 5.90), P < 0.00001], and sensory nerve conduction velocity (common peroneal nerve) by 3.60 m/s [MD = 3.60, 95% CI = (2.49, 4.71), P < 0.00001], and trial sequential analysis showed these benefits were conclusive. In terms of safety endpoints, meta-analysis indicated that the total adverse events for acupoint injection were comparable to other methods of administration, and trial sequential analysis suggested that the results needed to be validated by more studies. Subgroup analysis demonstrated that the benefits of acupoint injections of mecobalamin were not limited by the dose, duration of treatment, or number of acupoints reported in the included studies. Harbord's test showed no significant publication bias (P = 0.106). CONCLUSION: The efficacy of acupoint injection of mecobalamin for DPN was significantly better than other administrations, and its safety was comparable to other administrations. Therefore, acupoint injection may be the optimal method of mecobalamin for DPN. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=454120, identifier: CRD42023454120. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10619916/ /pubmed/37920836 http://dx.doi.org/10.3389/fneur.2023.1186420 Text en Copyright © 2023 Zhang, Yu, Yin, Hu, Yang, Tong and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Zhang, Fei Yu, Yunfeng Yin, Shuang Hu, Gang Yang, Xinyu Tong, Keke Yu, Rong Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title | Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title_full | Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title_fullStr | Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title_full_unstemmed | Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title_short | Is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? A meta-analysis and trial sequential analysis |
title_sort | is acupoint injection the optimal way to administer mecobalamin for diabetic peripheral neuropathy? a meta-analysis and trial sequential analysis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619916/ https://www.ncbi.nlm.nih.gov/pubmed/37920836 http://dx.doi.org/10.3389/fneur.2023.1186420 |
work_keys_str_mv | AT zhangfei isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT yuyunfeng isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT yinshuang isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT hugang isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT yangxinyu isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT tongkeke isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis AT yurong isacupointinjectiontheoptimalwaytoadministermecobalaminfordiabeticperipheralneuropathyametaanalysisandtrialsequentialanalysis |